OPKO Health (NASDAQ:OPK) Sees Unusually-High Trading Volume on Insider Buying Activity

OPKO Health, Inc. (NASDAQ:OPK) saw unusually-high trading volume on Wednesday following insider buying activity. Approximately 3,744,040 shares traded hands during trading, a decline of 8% from the previous session’s volume of 4,068,860 shares.The stock last traded at $1.67 and had previously closed at $1.66.

Specifically, CEO Phillip Md Et Al Frost acquired 100,000 shares of the company’s stock in a transaction dated Tuesday, April 1st. The stock was bought at an average price of $1.65 per share, with a total value of $165,000.00. Following the completion of the transaction, the chief executive officer now directly owns 213,751,448 shares of the company’s stock, valued at approximately $352,689,889.20. The trade was a 0.05 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Phillip Md Et Al Frost bought 150,000 shares of the business’s stock in a transaction dated Friday, March 28th. The stock was acquired at an average cost of $1.70 per share, for a total transaction of $255,000.00. Following the purchase, the chief executive officer now owns 213,651,448 shares in the company, valued at approximately $363,207,461.60. This trade represents a 0.07 % increase in their position. The disclosure for this purchase can be found here.

Wall Street Analyst Weigh In

OPK has been the subject of several recent research reports. HC Wainwright reiterated a “buy” rating and issued a $3.00 price target on shares of OPKO Health in a report on Wednesday, March 19th. StockNews.com upgraded OPKO Health from a “sell” rating to a “hold” rating in a report on Monday, March 3rd. Finally, Barrington Research restated an “outperform” rating and issued a $2.25 price target on shares of OPKO Health in a report on Wednesday, March 12th.

OPKO Health Price Performance

The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.69 and a current ratio of 2.97. The business’s fifty day simple moving average is $1.69 and its 200 day simple moving average is $1.58. The stock has a market cap of $1.11 billion, a price-to-earnings ratio of -8.68 and a beta of 1.70.

OPKO Health (NASDAQ:OPK) last posted its quarterly earnings data on Thursday, February 27th. The biotechnology company reported $0.01 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.09. The company had revenue of $183.60 million for the quarter, compared to the consensus estimate of $155.42 million. OPKO Health had a negative return on equity of 9.76% and a negative net margin of 18.65%. Research analysts predict that OPKO Health, Inc. will post -0.25 EPS for the current fiscal year.

Hedge Funds Weigh In On OPKO Health

A number of hedge funds have recently bought and sold shares of the company. Barclays PLC grew its position in shares of OPKO Health by 154.5% in the 3rd quarter. Barclays PLC now owns 543,336 shares of the biotechnology company’s stock worth $810,000 after acquiring an additional 329,870 shares in the last quarter. BNP Paribas Financial Markets boosted its holdings in OPKO Health by 736.7% in the third quarter. BNP Paribas Financial Markets now owns 246,967 shares of the biotechnology company’s stock worth $368,000 after purchasing an additional 217,450 shares during the period. Intech Investment Management LLC bought a new stake in OPKO Health during the third quarter valued at $190,000. FMR LLC lifted its position in shares of OPKO Health by 103.6% in the 3rd quarter. FMR LLC now owns 21,795 shares of the biotechnology company’s stock worth $32,000 after buying an additional 11,089 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd bought a new position in shares of OPKO Health in the 4th quarter worth about $102,000. 64.63% of the stock is currently owned by institutional investors and hedge funds.

About OPKO Health

OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals businesses in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories that offers laboratory testing services for the detection, diagnosis, evaluation, monitoring, and treatment of diseases, including esoteric testing, molecular diagnostics, anatomical pathology, genetics, women's health, and correctional healthcare to physician offices, clinics, hospitals, employers, and governmental units; and 4Kscore prostate cancer test.